拜西欧斯

Biosyous is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies for solid tumors. The company focuses on Tumor-Infiltrating Lymphocyte (TIL) therapy, CAR-T, and TCR-T technologies to address unmet medical needs in oncology. Its lead candidate, BST02, is a TIL therapy targeting advanced solid tumors and has received IND approval in both China and the US. Biosyous leverages its proprietary cell expansion and modification platforms to enhance the efficacy and persistence of immune cells within the immunosuppressive tumor microenvironment. The company is supported by prominent venture capital firms and maintains a robust pipeline of candidates targeting various solid malignancies. Biosyous aims to provide curative options for patients with refractory cancers through its advanced cell engineering capabilities.